Edmund Sonuga-Barke – författare
Visar alla böcker från författaren Edmund Sonuga-Barke. Handla med fri frakt och snabb leverans.
3 produkter
3 produkter
E-bok
PDF, Engelska, 2015397 kr
Läs direkt efter köp
This pocketbook serves as a concise and practical guide to the management of ADHD for child and adolescent psychiatrists and child psychologists, paediatricians, trainees, psychiatric specialist nurses, interested general practitioners, and other mental health professionals. The pocketbook provides a user-friendly introduction to the clinical understanding, evaluation, and treatment of ADHD. This edition has been updated to include new DSM-5 diagnostic criteria (May 2013) and to reflect more published studies on ADHD in the adult population, along with new data on the CNS stimulant drug LDX (Lisdexamfetamine Dimesylate).
E-bok
Engelska, 2015393 kr
Läs direkt efter köp
This pocketbook serves as a concise and practical guide to the management of ADHD for child and adolescent psychiatrists and child psychologists, paediatricians, trainees, psychiatric specialist nurses, interested general practitioners, and other mental health professionals. The pocketbook provides a user-friendly introduction to the clinical understanding, evaluation, and treatment of ADHD. This edition has been updated to include new DSM-5 diagnostic criteria (May 2013) and to reflect more published studies on ADHD in the adult population, along with new data on the CNS stimulant drug LDX (Lisdexamfetamine Dimesylate).
Häftad, Engelska, 2015
644 kr
Skickas inom 7-10 vardagar
This pocketbook serves as a concise and practical guide to the management of ADHD for child and adolescent psychiatrists and child psychologists, paediatricians, trainees, psychiatric specialist nurses, interested general practitioners, and other mental health professionals. The pocketbook provides a user-friendly introduction to the clinical understanding, evaluation, and treatment of ADHD. This edition has been updated to include new DSM-5 diagnostic criteria (May 2013) and to reflect more published studies on ADHD in the adult population, along with new data on the CNS stimulant drug LDX (Lisdexamfetamine Dimesylate).